The effect of dextromethorphan on the severity of symptoms in patients with resistant OCD

The effect of dextromethorphan on the severity of symptoms in patients with resistant obsessive-compulsive disorder: A triple blinded, randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120520009801N6

Enrollment

Registered

2021-11-02

Start date

2022-04-19

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Patients are selected from outpatients who visit the clinic of EbneSina Hospital. In the intervention group, patients diagnosed with obsessive-compulsive disorder, who meet the inclusi

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: OCD patients who have been treated with high doses of SSRI for at least 8 weeks but have a Y-BOCS index score higher than 10. (High doses of SSRI includ: Sertraline 200mg/day, Paroxetine 60mg/day, Fluoxetine 80mg/day and Fluvoxamine mg/day) subjects aged 18 to 60 years Obtaining the patient's informed consent

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Using serotonergic drugs other than SSRIs Use of NMDA receptor antagonists other than dextromethorphan and memantine Psychotic and bipolar disorders (based on DSM-5 criteria) past medical history of Liver dysfunction (LFT> 3ULN) past medical history of Kidney dysfunction (GFR <60 ml / kg / min) past medical history of Thyroid Disorders History of seizures

Design outcomes

Primary

Measure	Time frame
Evaluation of the effect of dextromethorphan in comparison with placebo on reducing the severity of symptoms in patients with obsessive-compulsive disorder based on (Y-BOCS) YALE-BROWN OBSESSIVE COMPULSIVE SCALE. Timepoint: Before intervention and 1 month, 2 months and 3 months after intervention. Method of measurement: Yale–Brown Obsessive Compulsive Scale.	—

Secondary

Measure	Time frame
Comparison of changes in executive functions in different groups. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Delis-Kaplan Executive Function System (D-KEFS) tests.;Adverse effect of drugs. Timepoint: In the first, second, and third months of using the medication, and whenever the patient experienced a complication, there was the possibility of contacting the clinical pharmacist who was aware of the types of codes.(However, she did not participate in any of the randomization, drug administration, or data analysis processes.). Method of measurement: patients declaration.	—

Measure

Time frame

Comparison of changes in executive functions in different groups. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Delis-Kaplan Executive Function System (D-KEFS) tests.;Adverse effect of drugs. Timepoint: In the first, second, and third months of using the medication, and whenever the patient experienced a complication, there was the possibility of contacting the clinical pharmacist who was aware of the types of codes.(However, she did not participate in any of the randomization, drug administration, or data analysis processes.). Method of measurement: patients declaration.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadpour Amir Hooshang

Mashhad University of Medical Sciences

mohamadpoorah@mums.ac.ir+98 51 1882 3255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026